Unknown

Dataset Information

Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency.


ABSTRACT:

Objective

On the basis of our previous work with triheptanoin, which provides key substrates to the Krebs cycle in the brain, we wished to assess its therapeutic effect in patients with glucose transporter type 1 deficiency syndrome (GLUT1-DS) who objected to or did not tolerate ketogenic diets.

Methods

We performed an open-label pilot study with three phases of 2 months each (baseline, treatment and withdrawal) in eight patients with GLUT1-DS (7-47 years old) with non-epileptic paroxysmal manifestations. We used a comprehensive patient diary to record motor and non-motor paroxysmal events. Functional (31)P-NMR spectroscopy was performed to quantify phosphocreatine (PCr) and inorganic phosphate (Pi) within the occipital cortex during (activation) and after (recovery) a visua

SUBMITTER: Mochel F 

PROVIDER: S-EPMC4853553 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature